Capital Performance Advisors LLP Neurocrine Biosciences Inc Transaction History
Capital Performance Advisors LLP
- $325 Million
- Q3 2024
A detailed history of Capital Performance Advisors LLP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Capital Performance Advisors LLP holds 144 shares of NBIX stock, worth $19,807. This represents 0.0% of its overall portfolio holdings.
Number of Shares
144Holding current value
$19,807% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
627Shares Held
94MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$1.95 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.38 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$708 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$354 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$256 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.2B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...